TY - JOUR
T1 - Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer
T2 - Updated survival analysis of JBR-10
AU - Butts, Charles A.
AU - Ding, Keyue
AU - Seymour, Lesley
AU - Twumasi-Ankrah, Philip
AU - Graham, Barbara
AU - Gandara, David
AU - Johnson, David H.
AU - Kesler, Kenneth A.
AU - Green, Mark
AU - Vincent, Mark
AU - Cormier, Yvon
AU - Goss, Glenwood
AU - Findlay, Brian
AU - Johnston, Michael
AU - Tsao, Ming Sound
AU - Shepherd, Frances A.
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.
AB - Purpose: Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC). Long-term follow-up is important to document persistent benefit and late toxicity. We report here updated overall survival (OS) and disease-specific survival (DSS) data. Patients and Methods: Patients with completely resected stage IB (T2N0, n = 219) or II (T1-2N1, n = 263) NSCLC were randomly assigned to receive 4 cycles of vinorelbine/cisplatin or observation. All efficacy analyses were performed on an intention-to-treat basis. Results: Median follow-up was 9.3 years (range, 5.8 to 13.8; 33 lost to follow-up); there were 271 deaths in 482 randomly assigned patients. ACT continues to show a benefit (hazard ratio [HR], 0.78; 95% CI, 0.61 to 0.99; P = .04). There was a trend for interaction with disease stage (P = .09; HR for stage II, 0.68; 95% CI, 0.5 to 0.92; P = .01; stage IB, HR, 1.03; 95% CI, 0.7 to 1.52; P = .87). ACT resulted in significantly prolonged DSS (HR, 0.73; 95% CI, 0.55 to 0.97; P = .03). Observation was associated with significantly higher risk of death from lung cancer (P = .02), with no difference in rates of death from other causes or second primary malignancies between the arms. Conclusion: Prolonged follow-up of patients from the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm.
UR - http://www.scopus.com/inward/record.url?scp=73949154000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949154000&partnerID=8YFLogxK
U2 - 10.1200/JCO.2009.24.0333
DO - 10.1200/JCO.2009.24.0333
M3 - Article
C2 - 19933915
AN - SCOPUS:73949154000
SN - 0732-183X
VL - 28
SP - 29
EP - 34
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 1
ER -